CORT
Corcept Therapeutics Incorporated
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Strong buy
+66/100
Last price
120.93
▼ 1.10 (0.91%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
122.15
Prev close
122.03
Day high
122.54
Day low
115.11
Volume
790.02K
Market cap
$12.93B
P/E (TTM)
271.75
52W range
28.66 – 126.38
Day trading desk
Gap from prior close
+0.10%
Prior close 122.03
VWAP
119.24
+1.42% from price
Relative volume
0.91×
Normal
Session range
7.51%
115.11 – 123.76
Position in range
67%
Mid range
ATR (14D)
5.97
4.94% of price
Prior day high
122.81
PDH
Prior day low
115.50
PDL
Bid / ask spread
—
Quote not published
Session volume
1.19M
Avg 1.31M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+4.21%
+2.3%
1M
+7.12%
+6.0%
3M
+28.65%
+24.1%
6M
+186.81%
+168.6%
YTD
+243.59%
+229.3%
1Y
+35.64%
+19.2%
3Y
+338.79%
+256.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CORT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+1.02M
Net buying
Buy transactions
44
1.90M shares
Sell transactions
35
877.29K shares
Net transactions
+79
Buys less sells
Sell : buy shares
0.5 : 1
Mixed
Insider-held shares
12.38M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 2, 26 | VIEIRA ROBERTO W Officer |
CONVERSION | 8.33K | $180.24K | Direct |
| Oct 2, 26 | MADUCK SEAN Officer |
CONVERSION | 25.00K | $206.75K | Direct |
| Oct 2, 26 | LYON JOSEPH DOUGLAS Chief Technology Officer |
CONVERSION | 10.00K | $168.85K | Direct |
| Oct 2, 26 | VIEIRA ROBERTO W Officer |
SELL | 8.33K | $967.45K | Direct |
| Oct 2, 26 | LYON JOSEPH DOUGLAS Chief Technology Officer |
SELL | 10.00K | $1.16M | Direct |
| Oct 2, 26 | MADUCK SEAN Officer |
SELL | 25.00K | $2.91M | Direct |
| Sep 24, 26 | ROBB GARY CHARLES Officer |
STOCK | 17.10K | $0 | Direct |
| Sep 15, 26 | WILSON JAMES N Director |
SELL | 10.00K | $1.11M | Indirect |
| Sep 14, 26 | LYON JOSEPH DOUGLAS Chief Technology Officer |
CONVERSION | 10.00K | $129.86K | Direct |
| Sep 14, 26 | LYON JOSEPH DOUGLAS Chief Technology Officer |
SELL | 10.00K | $1.13M | Direct |
| Sep 2, 26 | VIEIRA ROBERTO W Officer |
CONVERSION | 58.33K | $1.26M | Direct |
| Sep 2, 26 | VIEIRA ROBERTO W Officer |
SELL | 58.33K | $6.46M | Direct |
| Sep 1, 26 | MADUCK SEAN Officer |
CONVERSION | 25.00K | $206.75K | Direct |
| Sep 1, 26 | MADUCK SEAN Officer |
SELL | 25.00K | $2.86M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAKER GEORGE LEONARD JR. |
Director | 5.55M | Purchase |
BELANOFF JOSEPH K |
Chief Executive Officer | — | Sale |
GUYER WILLIAM |
Officer | 4.31K | Stock Award(Grant) |
HUNT HAZEL |
Officer | 255.44K | Conversion of Exercise of derivative security |
LYON JOSEPH DOUGLAS |
Chief Technology Officer | 5.68K | Conversion of Exercise of derivative security |
MADUCK SEAN |
Officer | 119.66K | Conversion of Exercise of derivative security |
MAHONEY DAVID L |
Director | — | Sale |
MOKARI ATABAK |
Chief Financial Officer | 16.30K | Stock Award(Grant) |
ROBB GARY CHARLES |
Officer | 74.34K | Stock Gift |
WILSON JAMES N |
Director | — | Sale |
Fundamentals
Market cap$12.93B
Enterprise value$12.63B
Revenue (TTM)$830.81M
Gross profit$816.73M
EBITDA$8.08M
Net income$54.27M
EPS (TTM)$0.44
Free cash flow$77.40M
Total cash$308.20M
Total debt$9.42M
Book value / share$6.54
Shares outstanding108.10M
Float96.48M
Short % of float11.14%
Dividend yield0.00%
Beta (5Y)0.40
Valuation & profitability ratios
Trailing P/E271.75
Forward P/E27.16
PEG ratio0.81
Price / sales—
Price / book18.28
EV / revenue15.20
EV / EBITDA1,561.92
Gross margin98.30%
Operating margin16.12%
Profit margin6.64%
Return on equity8.23%
Return on assets0.47%
Debt / equity1.34
Current ratio2.86
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $761.41M | $675.04M | $482.38M | $401.86M | — | +12.8% |
| Operating revenue | $761.41M | $675.04M | $482.38M | $401.86M | — | +12.8% |
| Cost of revenue | $12.98M | $10.88M | $6.48M | $5.38M | — | +19.3% |
| Gross profit | $748.43M | $664.16M | $475.89M | $396.47M | — | +12.7% |
| Research & development | $254.91M | $246.89M | $184.35M | $130.99M | — | +3.2% |
| Selling, general & admin | $448.73M | $280.32M | $184.26M | $152.85M | — | +60.1% |
| Total operating expense | $703.63M | $527.21M | $368.61M | $283.84M | — | +33.5% |
| Operating income | $44.80M | $136.95M | $107.28M | $112.63M | — | -67.3% |
| Net interest income | $21.67M | $24.54M | $17.27M | $3.56M | — | -11.7% |
| Pre-tax income | $66.46M | $161.49M | $124.56M | $116.19M | — | -58.8% |
| Tax provision | -$33.19M | $20.28M | $18.42M | $14.77M | — | -263.6% |
| Net income | $99.65M | $141.21M | $106.14M | $101.42M | — | -29.4% |
| Net income to common | $98.17M | $139.73M | $105.50M | $101.29M | — | -29.7% |
| Basic EPS | 0.95 | 1.35 | 1.02 | 0.95 | — | -29.6% |
| Diluted EPS | 0.82 | 1.23 | 0.94 | 0.87 | — | -33.3% |
| EBIT | $44.80M | $136.95M | $107.28M | $112.63M | — | -67.3% |
| EBITDA | — | — | — | $116.08M | $127.95M | — |
| Basic shares | 103.86M | 103.23M | 103.56M | 106.79M | — | +0.6% |
| Diluted shares | 119.99M | 113.48M | 111.74M | 115.97M | — | +5.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $120.50M | $127.67M | $135.55M | $66.33M | -5.6% |
| Cash & short-term investments | $372.15M | $383.33M | $368.22M | $431.67M | -2.9% |
| Accounts receivable | $59.79M | $53.98M | $41.12M | $31.06M | +10.8% |
| Inventory | $12.87M | $12.41M | $7.73M | $6.10M | +3.7% |
| Total current assets | $485.46M | $471.60M | $458.64M | $499.25M | +2.9% |
| Property, plant & equipment | $6.47M | $8.01M | $315.00K | $1.78M | -19.2% |
| Total assets | $836.65M | $840.55M | $621.52M | $583.43M | -0.5% |
| Total current liabilities | $166.09M | $140.77M | $104.50M | $72.49M | +18.0% |
| Total debt | $6.11M | $6.94M | $151.00K | $1.14M | -12.0% |
| Total liabilities | $188.85M | $160.96M | $114.81M | $81.59M | +17.3% |
| Retained earnings | $643.39M | $543.74M | $402.53M | $296.39M | +18.3% |
| Shareholder equity | $647.80M | $679.59M | $506.70M | $501.84M | -4.7% |
| Working capital | $319.38M | $330.83M | $354.13M | $426.76M | -3.5% |
| Net tangible assets | $647.80M | $679.59M | $506.70M | $501.84M | -4.7% |
| Shares issued | 142.52M | 137.75M | 134.34M | 130.96M | +3.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $99.65M | $141.21M | $106.14M | $101.42M | -29.4% |
| Depreciation & amortisation | $1.89M | $1.34M | $2.36M | $3.45M | +41.5% |
| Stock-based compensation | $84.50M | $61.35M | $48.94M | $42.44M | +37.7% |
| Change in working capital | -$1.41M | $45.52M | $7.86M | $5.54M | -103.1% |
| Operating cash flow | $142.00M | $198.29M | $126.68M | $120.32M | -28.4% |
| Capital expenditure | -$211.00K | -$2.17M | -$139.00K | -$413.00K | +90.3% |
| Investing cash flow | $69.76M | -$177.60M | $90.91M | -$114.33M | +139.3% |
| Share buybacks | $0 | $0 | -$145.43M | $0 | — |
| Financing cash flow | -$220.37M | -$28.35M | -$148.72M | -$17.28M | -677.3% |
| Free cash flow | $141.78M | $196.12M | $126.54M | $119.91M | -27.7% |
| End cash position | $120.50M | $127.67M | $135.55M | $66.33M | -5.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $256.15M | $164.90M | $202.13M | $207.64M | $194.43M | +55.3% |
| Operating revenue | $256.15M | $164.90M | $202.13M | $207.64M | $194.43M | +55.3% |
| Cost of revenue | $4.06M | $2.88M | $2.54M | $4.60M | $3.43M | +40.9% |
| Gross profit | $252.09M | $162.02M | $199.58M | $203.04M | $191.00M | +55.6% |
| Research & development | $53.89M | $66.27M | $64.86M | $68.85M | $60.47M | -18.7% |
| Selling, general & admin | $156.90M | $145.36M | $130.24M | $123.98M | $103.85M | +7.9% |
| Total operating expense | $210.79M | $211.62M | $195.09M | $192.82M | $164.32M | -0.4% |
| Operating income | $41.30M | -$49.60M | $4.49M | $10.22M | $26.68M | +183.3% |
| Net interest income | $4.63M | $4.89M | $5.42M | $5.02M | $5.02M | -5.2% |
| Pre-tax income | $45.93M | -$44.72M | $9.91M | $15.24M | $31.69M | +202.7% |
| Tax provision | $2.94M | -$12.95M | -$14.38M | -$4.42M | -$3.46M | +122.7% |
| Net income | $42.99M | -$31.76M | $24.29M | $19.67M | $35.15M | +235.3% |
| Net income to common | $42.14M | -$31.20M | $23.90M | $19.36M | $34.61M | +235.1% |
| Basic EPS | 0.40 | -0.30 | 0.23 | 0.19 | 0.33 | +233.3% |
| Diluted EPS | 0.36 | -0.30 | 0.20 | 0.16 | 0.29 | +220.0% |
| EBIT | $41.30M | — | — | — | — | — |
| EBITDA | $42.16M | -$49.00M | $4.97M | $10.70M | $27.14M | +186.0% |
| Basic shares | 105.38M | 104.44M | 103.69M | 103.55M | 104.11M | +0.9% |
| Diluted shares | 118.39M | 104.44M | 119.86M | 119.44M | 120.48M | +13.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $111.04M | $108.74M | $120.50M | $125.14M | $102.75M | +2.1% |
| Cash & short-term investments | $308.20M | $338.18M | $372.15M | $421.68M | $342.23M | -8.9% |
| Accounts receivable | $76.92M | $39.07M | $59.79M | $69.63M | $64.57M | +96.9% |
| Inventory | $13.19M | $12.89M | $12.87M | $12.35M | $12.28M | +2.3% |
| Total current assets | $439.68M | $426.03M | $485.46M | $541.13M | $443.11M | +3.2% |
| Property, plant & equipment | $11.99M | $10.37M | $6.47M | $6.87M | $7.31M | +15.7% |
| Total assets | $888.70M | $814.88M | $836.65M | $823.61M | $801.72M | +9.1% |
| Total current liabilities | $153.80M | $149.19M | $166.09M | $172.26M | $144.66M | +3.1% |
| Total debt | $9.42M | $9.64M | $6.11M | $6.36M | $6.61M | -2.2% |
| Total liabilities | $182.93M | $176.89M | $188.85M | $191.71M | $165.93M | +3.4% |
| Retained earnings | $654.61M | $611.63M | $643.39M | $619.10M | $599.43M | +7.0% |
| Shareholder equity | $705.78M | $637.99M | $647.80M | $631.90M | $635.79M | +10.6% |
| Working capital | $285.87M | $276.85M | $319.38M | $368.87M | $298.45M | +3.3% |
| Net tangible assets | $705.78M | $637.99M | $647.80M | $631.90M | $635.79M | +10.6% |
| Shares issued | 107.92M | 143.88M | 142.52M | 141.12M | 106.04M | -25.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $42.99M | -$31.76M | $24.29M | $19.67M | $35.15M | — | +235.3% |
| Depreciation & amortisation | $863.00K | $598.00K | $482.00K | $477.00K | $469.00K | — | +44.3% |
| Stock-based compensation | $29.42M | $23.04M | $20.77M | $22.88M | $19.02M | — | +27.7% |
| Change in working capital | -$41.90M | $5.29M | $9.19M | $3.35M | $8.73M | — | -891.4% |
| Operating cash flow | $33.54M | -$16.77M | $38.45M | $54.48M | $44.30M | — | +300.0% |
| Capital expenditure | -$2.53M | -$201.00K | -$50.00K | — | -$57.00K | -$104.00K | -1,157.7% |
| Investing cash flow | -$29.24M | $4.54M | -$11.84M | $14.64M | $70.13M | — | -743.8% |
| Financing cash flow | -$2.04M | $760.00K | -$31.22M | -$46.41M | -$102.93M | — | -368.0% |
| Free cash flow | $31.02M | -$16.97M | $38.40M | $54.48M | $44.24M | — | +282.7% |
| End cash position | $112.29M | $109.99M | $120.50M | $125.14M | $103.75M | — | +2.1% |
Options analytics
Put / call volume
0.75
Call-heavy session
Put / call open interest
1.00
Positioning, not flow
Max pain
115.00
-3.8% from spot
ATM implied vol
49.5%
Nearest strike to spot
Skew (10% OTM)
+5.5%
Puts bid over calls
Call volume
167
Contracts, this expiry
Put volume
126
Contracts, this expiry
Heaviest call OI
120.00
412 contracts
Heaviest put OI
100.00
430 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.06 | 0.36 | +535.3% |
| Mar 2026 | -0.14 | -0.30 | -111.3% |
| Dec 2025 | 0.33 | 0.20 | -39.4% |
| Sep 2025 | 0.14 | 0.16 | +18.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.87 | 4 | $336.37M | +62.0% |
| Next quarter | 1.21 | 4 | $388.75M | +92.3% |
| Current year | 2.15 | 4 | $1.15B | +50.5% |
| Next year | 4.40 | 4 | $1.70B | +48.8% |
Analyst targets & ownership
Mean target$141.00
High target$165.00
Low target$50.00
Implied upside16.60%
Analyst count5
ConsensusNONE
Strong buy / Buy1 / 3
Hold0
Sell / Strong sell1 / 0
Held by insiders11.45%
Held by institutions76.89%
Institutions holding544
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
116.50
+3.80% from price
SMA 20
114.96
+4.01% from price
SMA 50
114.10
+4.79% from price
SMA 100
97.00
+24.66% from price
SMA 200
70.31
+70.05% from price
EMA 12
116.59
+3.72% from price
EMA 26
114.98
+5.17% from price
EMA 50
110.31
+9.63% from price
RSI (14)
57.4
Neutral
MACD (12,26,9)
1.61
Hist 0.38
ATR (14)
5.97
4.99% of price
Realised vol 30D
37.6%
Annualised
Bollinger upper
120.70
20, 2σ
Bollinger lower
109.23
20, 2σ
50 / 200 cross
Golden
114.10 vs 70.31
Trend bias
Above 200
+70.05%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.85
More volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
37.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-64.4%
Peak to trough
Max drawdown 5Y
-71.9%
Peak to trough
ATR 14
5.97
4.99% of price
Beta (reported)
0.40
5Y monthly, from filing
Short interest
Shares short
9.35M
Prior 9.70M
Change vs prior
-3.6%
Shorts covering
% of float
11.14%
Elevated
% of shares out
8.65%
Against total outstanding
Days to cover
10.7
Crowded exit
Float
96.48M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 30, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Jul 30, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jul 30, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 29, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jul 27, 26 | Wolfe Research | DOWNGRADE | Peer Perform | Underperform |
| May 28, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| May 28, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 13, 26 | UBS | UPGRADE | Neutral | Buy |
| May 4, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 1, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Mar 26, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-23
Periodic Financial Reports
10-Q · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-06-17
Corporate Changes & Voting Matters
8-K · 2026-06-03
Offering Registrations
S-8 · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-28
Periodic Financial Reports
10-Q · 2026-04-30
Proxy Statements
DEF 14A · 2026-04-17
Headlines
Corcept, IBD Stock Of The Day, Setting Up Amid Booming Earnings Growth
Investor's Business Daily · 7h ago
3 Reasons to Sell CORT and 1 Stock to Buy Instead
StockStory · 13h ago
Corcept Therapeutics Insider Sold Shares Worth $2,906,601, According to a Recent SEC Filing
MT Newswires · 20h ago
Corcept Therapeutics Insider Sold Shares Worth $1,160,731, According to a Recent SEC Filing
MT Newswires · 21h ago
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
Zacks · 2d ago
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
Zacks · 5d ago
Is Aspen Pharmacare (APNHY) Stock Outpacing Its Medical Peers This Year?
Zacks · 8d ago
Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT)
Insider Monkey · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.